The Stocks in Action || How S&P/ASX200 Performed As The US Bluechip Stocks Were On The Move?

This is The Stocks in Action show. First, let's look at ASX 200 and the ASX listed stocks that are trending today.  

• The benchmark index ASX 200 is up today, gaining 0.29 per cent to 7302.90 and setting a new 52-week high. The top performing stocks in this index are Mesoblast, up 5.65 per cent and Invocare, up 4.54 per cent. Over the last five days, the index has gained 2.24 per cent and is currently 0.17 per cent off of its 52-week high. 

• 9 of 11 sectors are higher along with the S&P/ASX 200 Index. A-REIT is the best performing sector, gaining 1.00 per cent and 4.83 per cent for the past five days. 

• The S&P/ASX 200 closed its session 0.19 per cent lower at 7,281.9, yesterday, on Monday, ending its three-day winning streak. However, before closing lower, the ASX 200 touched a new all-time high of 7,309.4.   

• The Aussie closed 0.4 per cent lower after gaining 1.04 per cent on Friday, while the New Zealand dollar was up by 0.2 per cent. 

• In the Cryptocurrency market, Bitcoin again fell below US$35,000 and is currently trading 4.4 per cent down, at US$34,191, the lowest level in June. Dogecoin is also down 9.5 per cent and Ethereum down 4.3 per cent (as of 7:16 AM AEST). 

• Crude oil prices slipped on Monday after reaching two-year high levels on OPEC's decision to curb production and an improved economic recovery leading to robust energy demand. 

• August delivery Brent crude oil futures traded flat at US$71.47 per barrel and WTI crude oil futures for July delivery traded 0.04 per cent down at US$69.20 per barrel as of 8 June 2021 at 10:13 AM AEST.

• Mobilicom Limited announced it has successfully completed delivery of more than AU$1.8 million of products for the AU$2.3 million contract with a leading global drone supplier, following shipment of over 200 additional units of its Ground Controller System. 

• Happy Valley Nutrition Limited gains as much as 6.7 per cent to AU$0.160, hitting its highest since 22 March 2021. 

• Immutep Limited, the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, has just shared an update on its preclinical development pipeline. 

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK